The post BNB Technical Analysis Feb 1 appeared on BitcoinEthereumNews.com. BNB is trading at $784.81 with a 7.99% drop intraday, requiring caution due to high volatilityThe post BNB Technical Analysis Feb 1 appeared on BitcoinEthereumNews.com. BNB is trading at $784.81 with a 7.99% drop intraday, requiring caution due to high volatility

BNB Technical Analysis Feb 1

BNB is trading at $784.81 with a 7.99% drop intraday, requiring caution due to high volatility and downward trend risks. Investors should focus on capital protection with stop loss strategies below the $749 support, and closely monitor BTC movements due to Bitcoin correlation.

Market Volatility and Risk Environment

BNB showed high volatility in the last 24 hours within the $750.00 – $853.46 range, implying over 10% daily fluctuation. With the current price at $784.81, RSI at 27.40 is near oversold territory, but the Supertrend bearish signal and lack of position above EMA20 ($871.47) create a short-term bearish environment. Multi-timeframe (MTF) analysis detects 11 strong levels on 1D/3D/1W charts: 1 support/2 resistances on 1D, 2 supports/1 resistance on 3D, 2 supports/3 resistances on 1W distribution. This indicates that resistance weight on the weekly timeframe keeps risk high. Using Average True Range (ATR) is critical for volatility assessment: Recent daily ATR hovers around $50-60 band, which can impact positions in 5-7% moves. In crypto markets, volatility can lead to sudden liquidity losses, so traders should add volatility buffers against tight stops for capital protection. Lack of concrete news flow highlights technical risks.

Risk/Reward Ratio Assessment

Potential Reward: Target Levels

In a bullish scenario, the $979.8509 target (score:16) offers about 25% upside potential from the current price. This level can be supported by EMA20 crossover and above $829.7150 resistance, but the low score reflects bearish pressures. For long-term reward, monitor weekly resistance breach ($798.6482 above), but since the trend is downtrend, R/R ratios may remain pessimistic (e.g., around 1:1.2).

Potential Risk: Stop Levels

Bearish target $570.9036 (score:22) carries 27% downside risk from current price and aligns with Supertrend resistance at $879.20. Main support $749.8831 (score:74/100), trade becomes invalid below here. If resistance $798.6482 (score:73/100) cannot be broken, risk may rise to 4-5%. To calculate risk/reward ratio: Use Stop distance / Target distance formula; current data with high bearish score warns of unbalanced R/R like 1:0.9.

Stop Loss Placement Strategies

Stop loss is the foundation of capital protection; for BNB, place ATR-based at structural support $749.8831 (e.g., ATR x 1.5 = $75 buffer, i.e., around $675 wide stop). Strategies: 1) Structural stop: Below recent low (%1-2 buffer at $740). 2) Volatility-adjusted: Dynamic stop with ATR multiplier (1-2x), if daily ATR $50 then stop $734-729. 3) Trailing stop: Pull back according to Supertrend on upside moves. Educational note: Setting stops too tight increases whipsaw risk, too wide causes capital erosion. For MTF alignment, use 1W supports (below $749) as invalidation; this protects the trade with 95+% probability. Never change stops emotionally – calculate first.

Position Sizing Considerations

Position size should be calculated based on the 1-2% risk rule of total portfolio: Formula: (Account Balance x Risk %) / (Entry – Stop Distance). Example: In $100K account with 1% risk ($1K), if stop 5% away, position is $20K. In BNB volatility, Kelly Criterion or fixed fractional methods are educational: When volatility is high (ATR > 5%), reduce size. In multiple positions, use correlation matrix (BNB-BTC 0.85+). Educational warning: In highly leveraged futures (BNB Futures Analysis), liquidation risk multiplies; prefer spot (BNB Spot Analysis). Large positions trigger psychological biases – stay disciplined.

Risk Management Conclusions

Key takeaways: Downtrend and bearish scores (27% downside > 25% upside) make R/R risky; stop below $749 mandatory. Do not exceed 1% portfolio risk with volatility buffer. MTF resistance weight requires caution in longs. Capital protection focus: Max 2% loss per trade, prevent annual 20+% drawdown. Even with RSI oversold, fakeout risk is high before trend reversal – patience is key.

Bitcoin Correlation

BNB is highly correlated with BTC (85+%); BTC at $79,036 in downtrend (24h -6.02%), Supertrend bearish. If BTC supports $78,804/$75,770 break, BNB dragged below $749. BTC resistance above $80,357 rally may allow BNB to $829. BTC dominance increase crushes altcoins – monitor below BTC $75K, delay BNB longs.

This analysis uses the market views and methodology of Chief Analyst Devrim Cacal.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/bnb-technical-analysis-1-february-2026-risk-and-stop-loss

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26